Literature DB >> 10453617

A clinical study on bing gan ling oral liquid for treatment of hepatitis C.

S You1, M Zhou, B Xue, T Fang, W Jiang, C Li, H Xu, J Jiang, Y Wang, S Xu.   

Abstract

Based on the principles of cooling the blood to expel the pathogenic toxins and regulating the function of liver and activating the spleen in traditional Chinese medicine, 60 cases of chronic hepatitis C were treated with Bing Gan Ling (BGL), an oral liquid, which is composed mainly of Shuiniujiao (Cornu Bubali), Huzhang (Rhizoma Polygoni Cuspidati), Chishao (Radix Paeoniae Rubra), and Huangqi (Radix Astragali), etc. The total effective rate was 86.7%, which is considerably better than that of the control group (P < 0.01). The animal experiments and pathological studies suggest that the above-mentioned prescription has marked action of protecting the liver and lowering the activity of enzymes; and that it can ameliorate the acute liver injury induced by D-galactosamine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10453617

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  4 in total

1.  Chinese herbal medicines and their efficacy in treating renal stones.

Authors:  Mayur Danny I Gohel; Siu Ping Wong
Journal:  Urol Res       Date:  2006-12

Review 2.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

3.  Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation.

Authors:  Miao-Xian Dong; Yan Jia; Ying-Bo Zhang; Cheng-Chong Li; Yu-Tao Geng; Li Zhou; Xue-Yan Li; Ji-Cheng Liu; Ying-Cai Niu
Journal:  World J Gastroenterol       Date:  2009-10-14       Impact factor: 5.742

4.  Emodin Alleviates Liver Fibrosis of Mice by Reducing Infiltration of Gr1hi Monocytes.

Authors:  Xiang-An Zhao; Guangmei Chen; Yong Liu; Hongyan Wu; Jin Chen; Yali Xiong; Chen Tian; Bei Jia; Guiyang Wang; Juan Xia; Yuxin Chen; Jian Wang; Xiaomin Yan; Zhaoping Zhang; Rui Huang; Chao Wu
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-21       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.